Investment
Features
FeesSafety
Academy
More
Pluang+

Corteva stock jumps 12% after multiple analyst upgrades post-separation

Analyst Insights
07 Oct 2026
Alex Lavoie
View Source
Bullish
Corteva stock jumps 12% after multiple analyst upgrades post-separation

Corteva's stock surged 12.27% to $13.91 on October 6 following upgrades from KeyBanc, JPMorgan, and Bank of America after its separation from the seed genetics business, Vylor. Analysts set price targets up to $19, indicating significant upside potential, and value the company at 8.5 times estimated 2027 EBITDA. The upgrades reflect optimism about Corteva's future as a standalone crop protection company and new product prospects amid tighter agricultural markets in 2027.

Corteva's stock surge follows analyst upgrades, with price targets reaching $19. For readers following the broader US market, here is Pluang's snapshot as of Oct 07, 2026 20:31 WIB: out of 150 priced US stocks, 41 rose and 107 fell. Notable movers include HOOD at USD 108.65 with a 1-day change of -2.99%, MU at USD 1,014.37 down 2.98%, and B at USD 39.53 down 2.92%.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
58 minutes ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
1 hour ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
2 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App